Skip to main content
Annovis Bio, Inc. logo

Annovis Bio, Inc. — Investor Relations & Filings

Ticker · ANVS ISIN · US03615A1088 LEI · 549300IFBVI51FN3NJ32 US Professional, scientific and technical activities
Filings indexed 290 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country US United States of America
Listing US ANVS

About Annovis Bio, Inc.

https://www.annovisbio.com/

Annovis Bio, Inc. is a clinical-stage drug platform company that develops therapies for neurodegenerative diseases. The company's primary focus is on conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead product candidate, buntanetap, is a translational inhibitor designed to halt the death of nerve cells by targeting the synthesis of multiple neurotoxic proteins. The company's therapeutic approach aims to restore nerve cell function, with the goal of improving cognitive and motor abilities in patients suffering from neurodegeneration.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings
2026-05-20 English
424B5
Prospectus
2026-05-20 English
424B5
Prospectus
2026-05-19 English
10-Q
Interim / Quarterly Report
2026-05-15 English
FORM 8-K
Regulatory Filings
2026-05-15 English
424B5 - Annovis Bio, Inc. (0001477845) (Filer)
Prospectus
2026-04-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.